PrimeBell

PrimeBell is a South Korean biotechnology company specializing in the development of advanced drug delivery systems designed to penetrate the blood-brain barrier (BBB). The company's core technology, the B-Shuttle platform, utilizes specific ligands to facilitate the transport of therapeutic payloads—including small molecules, antibodies, and peptides—into the central nervous system. PrimeBell focuses on addressing high unmet needs in neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as oncology indications like brain metastases. By enhancing the brain-targeting efficiency of existing and novel therapeutics, the company aims to improve treatment outcomes for complex neurological conditions.